CUSIP 92790C104 · who reports it, how much, and how much it matters to them
32 of the 720 hedge fund managers we track reported shares of Viridian Therapeutics, Inc. (Nasdaq: VRDN) on Form 13F for 30 June 2026. Between them they reported USD 550m. The largest position belongs to Kynam Capital Management, at USD 119m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Kynam Capital Management1 fund on PPLI.com | USD 119m | 6.6% |
| 2 | Fairmount Funds Management2 funds on PPLI.com | USD 94m | 6.2% |
| 3 | Deep Track Capital1 fund on PPLI.com | USD 66m | 1.0% |
| 4 | Avoro Capital Advisors1 fund on PPLI.com | USD 46m | 0.4% |
| 5 | Baker Bros. Advisors2 funds on PPLI.com | USD 44m | 0.2% |
| 6 | POINT72 Asset Management17 funds on PPLI.com | USD 43m | 0.0% |
| 7 | Balyasny Asset Management25 funds on PPLI.com | USD 24m | 0.0% |
| 8 | D. E. Shaw & Co.15 funds on PPLI.com | USD 22m | 0.0% |
| 9 | Eversept Partners3 funds on PPLI.com | USD 15m | 0.8% |
| 10 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 15m | 0.1% |
| 11 | Renaissance Technologies13 funds on PPLI.com | USD 14m | 0.0% |
| 12 | Perceptive Advisors6 funds on PPLI.com | USD 11m | 0.2% |
| 13 | Boothbay Fund Management2 funds on PPLI.com | USD 9.9m | 0.1% |
| 14 | Yiheng Capital Management1 fund on PPLI.com | USD 7.4m | 2.5% |
| 15 | Capital Fund Management S.A.12 funds on PPLI.com | USD 3.6m | 0.0% |
| 16 | Squarepoint Ops7 funds on PPLI.com | USD 3.3m | 0.0% |
| 17 | HighVista Strategies27 funds on PPLI.com | USD 2.9m | 0.7% |
| 18 | Lighthouse Investment Partners190 funds on PPLI.com | USD 2.2m | 0.1% |
| 19 | Voleon Capital Management13 funds on PPLI.com | USD 1.8m | 0.0% |
| 20 | Aquatic Capital Management3 funds on PPLI.com | USD 1.5m | 0.1% |
| 21 | Burkehill Global Management5 funds on PPLI.com | USD 1.2m | 0.0% |
| 22 | Tudor Investment Corporation10 funds on PPLI.com | USD 1.1m | 0.0% |
| 23 | Greenland Capital Management1 fund on PPLI.com | USD 918,000 | 0.1% |
| 24 | Citadel Advisors32 funds on PPLI.com | USD 759,000 | 0.0% |
| 25 | Verdad Advisers6 funds on PPLI.com | USD 711,000 | 0.7% |
| 26 | Persistent Asset Partners10 funds on PPLI.com | USD 468,000 | 0.1% |
| 27 | Bayforest Capital1 fund on PPLI.com | USD 363,000 | 0.3% |
| 28 | Brevan Howard Capital Management39 funds on PPLI.com | USD 358,000 | 0.0% |
| 29 | Graham Capital Management18 funds on PPLI.com | USD 282,000 | 0.0% |
| 30 | LMR Partners2 funds on PPLI.com | USD 184,000 | 0.0% |
| 31 | The Quarry1 fund on PPLI.com | USD 4,225 | 0.0% |
| 32 | Elequin Capital2 funds on PPLI.com | USD 1,304 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Kynam Capital Management | USD 119m | 6.6% |
| 2 | Fairmount Funds Management | USD 94m | 6.2% |
| 3 | Yiheng Capital Management | USD 7.4m | 2.5% |
| 4 | Deep Track Capital | USD 66m | 1.0% |
| 5 | Eversept Partners | USD 15m | 0.8% |
| 6 | Verdad Advisers | USD 711,000 | 0.7% |
| 7 | HighVista Strategies | USD 2.9m | 0.7% |
| 8 | Avoro Capital Advisors | USD 46m | 0.4% |
| 9 | Bayforest Capital | USD 363,000 | 0.3% |
| 10 | Baker Bros. Advisors | USD 44m | 0.2% |
Viridian Therapeutics, Inc. trades under the symbol VRDN on the Nasdaq. Its CUSIP, the code used on Form 13F, is 92790C104.
32 of the 720 hedge fund managers PPLI.com tracks reported Viridian Therapeutics, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Kynam Capital Management (USD 119m), Fairmount Funds Management (USD 94m), Deep Track Capital (USD 66m), Avoro Capital Advisors (USD 46m) and Baker Bros. Advisors (USD 44m).
32 managers in our coverage reported it, and between them they run 498 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Kynam Capital Management, where the position was 6.6% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Viridian Therapeutics, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.